Related Experiment Videos
[Immunosuppressive medication in multiple sclerosis]
1Servicio de Neurología, Clínica Puerta del Hierro, Madrid, España. gmerino@meditex.es
Revista De Neurologia
|December 24, 2002
Summary
Immunosuppressive drugs remain vital for multiple sclerosis (MS) treatment, even with new immunomodulators. Research reviews their use, alone or combined with immunomodulators, for better MS management.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Context:
- Multiple sclerosis (MS) treatment has evolved significantly with the introduction of immunomodulators.
- Immunosuppressive drugs, including newer agents like mitoxantrone, continue to play a role in MS management.
- Traditional efficacy studies for immunosuppressants often used outdated criteria, complicating current assessment.
Purpose:
- To review the established use of immunosuppressive drugs in multiple sclerosis (MS).
- To discuss the potential role of immunosuppressants in combination therapy with immunomodulators.
- To explore future therapeutic options involving immunosuppressive agents for MS.
Summary:
- Immunosuppressive drugs have a long history in treating multiple sclerosis (MS).
- Despite the advent of immunomodulators, immunosuppressants like mitoxantrone are still relevant.
- Assessing the precise indications for these drugs is challenging due to historical study limitations.
- Immunosuppressants may offer benefits when used alongside immunomodulators in MS therapy.
Impact:
- Provides a comprehensive overview of immunosuppressant utility in MS.
- Highlights the need for updated research to define optimal use of immunosuppressants.
- Informs clinical decisions regarding combination therapies for multiple sclerosis.
- Guides future research directions for immunosuppressive treatments in MS.